Filing Flows

Filing Flows › Companies › Viridian Therapeutics › Cash flow

Viridian Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$93.1M in Q3 2026 · −$343M over twelve months

Operating cash flow−$92.8M
Capital spending−$370K
Free cash flow−$93.1M

Analysis

In Q3 2026, Viridian Therapeutics generated −$92.8M of operating cash flow and spent $370K on capital projects, leaving free cash flow of −$93.1M. That is $8.4M less than in Q3 2025 (−$84.7M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$342M; the largest uses were other investing ($467M), operating cash flow ($342M), capital spending ($1.9M); besides operations, cash came from other financing ($618M), net borrowing (+) / repaid (−) ($130M); the cash balance rose by $4.5M.

Operating cash flow was −$92.8M against net income of −$101M. The largest differences: stock-based pay +$17.2M, accrued liabilities +$16.1M, payables +$1.2M.

Free cash flow

Viridian Therapeutics: free cash flow by quarterViridian Therapeutics: free cash flow by quarter−$73.4MQ4 2024−$92.7MQ1 2025−$75.4MQ2 2025−$84.7MQ3 2025−$24.0MQ4 2025−$120MQ1 2026−$107MQ2 2026−$93.1MQ3 2026
Operating cash flow less capital spending.
Viridian Therapeutics: operating cash flow against capital spendingViridian Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$73.3M$114KQ4 2024−$92.7M$86KQ1 2025−$75.4M$42KQ2 2025−$84.6M$127KQ3 2025−$23.8M$240KQ4 2025−$120M$23KQ1 2026−$105M$1.3MQ2 2026−$92.8M$370KQ3 2026
Latest (Q3 2026): Operating cash flow −$92.8M, Capital spending $370K.

Capital allocation, year by year

Viridian Therapeutics: where the cash came from (up) and went (down), by fiscal yearViridian Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$54.6MFY2021: Shares issued $132MFY2021: Asset sales $79KFY2021: Capital spending −$338K$132MFY2021FY2022: Operating cash flow −$93.8MFY2022: Net borrowing $5.0MFY2022: Shares issued $339MFY2022: Capital spending −$797K$344MFY2022FY2023: Operating cash flow −$184MFY2023: Net borrowing $15.0MFY2023: Shares issued $111MFY2023: Capital spending −$898K$126MFY2023FY2024: Operating cash flow −$232MFY2024: Shares issued $100MFY2024: Capital spending −$511K$100MFY2024FY2025: Operating cash flow −$276MFY2025: Net borrowing $28.9MFY2025: Shares issued $75.2MFY2025: Capital spending −$495K$104MFY2025
Over these 5 years operating cash flow totalled −$841M; the largest uses were operating cash flow ($841M) and capital spending ($3.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$955M
Debt$20.9M
Net cash$934M
Cash runway2.8 years

Viridian Therapeutics is burning cash: its operations consume cash, a free cash flow of −$343M a year at the current rate against $955M of cash and investments: a runway of about 2.8 years before any new financing.

Where the cash came from and went

Viridian Therapeutics: sources (+) and uses (−) of cash, Q3 2026Viridian Therapeutics: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$92.8MOther financing$74.0MOther investing$24.7MCash drawn (+) / kept (−)−$9.2MShares issued$3.6MCapital spending−$370K
Viridian Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Viridian Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$618MOther investing−$467MOperating cash flow−$342MNet borrowing (+) / repaid (−)$130MShares issued$67.2MCash drawn (+) / kept (−)−$4.5MCapital spending−$1.9M

From profit to cash

Viridian Therapeutics: net income to operating cash flow, Q3 2026Viridian Therapeutics: net income to operating cash flow, Q3 2026Net income−$101MDepreciation & amortization$343KStock-based pay$17.2MPayables$1.2MAccrued liabilities$16.1MPrepaid and other assets−$1.0MOther liabilities$106KOperating cash flow−$92.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$92.8M−$370K—$3.6M−$9.2M−$93.1M
Q2 2026−$105M−$1.3M—$577K$11.4M−$107M
Q1 2026−$120M−$23K—$6.4M$36.0M−$120M
Q4 2025−$23.8M−$240K$55.0M$56.7M−$42.7M−$24.0M
Q3 2025−$84.6M−$127K—$10.5M−$52.3M−$84.7M
Q2 2025−$75.4M−$42K—$764K−$1.1M−$75.4M
Q1 2025−$92.7M−$86K—$7.2M−$16.6M−$92.7M
Q4 2024−$73.3M−$114K—$36.8M$101M−$73.4M

Viridian Therapeutics: income statement and cash flow

Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%. The chart follows the revenue to costs, profit and cash.

Viridian Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.